EIT Health invests €3M in innovations for endometrial cancer and Parkinson’s disease

Posted on

EU-backed properly being innovators, EIT Well being instantly launched their assist for two innovator teams following their 2020 Wild Card programme, selecting Spain-based MiMARK and German-based Orbit Well being.

The 2 teams may be supported by EIT Well being, which is backed by the EU as part of the European Institute of Innovation and Know-how, for over two years with as a lot as €1.5 million each.

Along with the financial assist, EIT Well being offers mentoring and coaching, along with entry to its neighborhood all through Europe.

WHY IT MATTERS

The EIT Well being Wild Card programme builds life science corporations to interrupt new flooring in properly being by tough the established order in areas of unmet need.

Starting with two challenges set by EIT Well being, the annual Wild Card programme invites innovators from all through Europe to answer with their ideas. Profitable people pitch their decision to a panel of enterprise leaders to secure a spot inside the finals, at which stage they pitch for EIT Well being funding to incorporate their agency and produce their decision to market.

MiMARK, from Barcelona, Spain will focus on bettering the accuracy and effectivity of diagnostics for endometrial most cancers, which in accordance with the World Most cancers Analysis Fund, is the sixth principally occurring most cancers in women. Early detection of the sickness is linked to elevated survival, nonetheless in the meanwhile spherical a third of endometrial most cancers victims are acknowledged on the superior stage. By bettering the know-how on the market for the evaluation of endometrial most cancers, MiMARK objectives to reinforce the rate and accuracy at which women may be acknowledged and dealt with.

Orbit Well being from Munich, Germany will focus on rising an AI decision to permit the personalisation of treatment for Parkinson’s sickness. Parkinson’s is the most common neurodegenerative state of affairs after Alzheimer’s, affecting an estimated 1.2 million in Europe. The company analyses the way in which wherein whereby each affected individual responds to their treatment using know-how that could be built-in into medical comply with. This permits clinicians to prescribe a treatment regime to most interesting administration indicators and improve the usual of lifetime of victims with Parkinson’s sickness.

THE LARGER CONTEXT

In July 2020, the European Institute of Innovation and Know-how (EIT) Well being Wild Card programme launched collectively 45 people to go looking out choices in areas of extreme unmet need inside women’s properly being and digital therapeutics. 

ON THE RECORD

Jorge Juan Fernández García, director of innovation, EIT Well being said: “In session with enterprise consultants, we chosen women’s properly being and digital therapeutics as areas in need of innovation and with potential to reinforce the lives of victims and residents all through Europe and previous. The experience that we seen all through ultimate 12 months’s Wild Card programme is unparalleled, and we’re thrilled to have now chosen MiMARK and Orbit Well being to hitch the EIT Well being family and help us deal with a couple of of the toughest properly being challenges that proceed to affect hundreds and hundreds of people day by day. We look ahead to supporting them at every step of their journey and dealing collectively to ship new choices which will change lives.”

Eva Colás Ortega, principal researcher of the biomedical evaluation group in gynaecology of the Vall Hebron Institute of Analysis, the Gynaecology Service of Hospital Vall d’Hebron, and co-founder of MiMARK said: “With our resolution, we hope to alter the usual of look after endometrial most cancers by offering innovation in diagnostic know-how at an early stage and with out the necessity for invasive and uncomfortable procedures.”

Patty Lee, CEO and co-founder of Orbit Well being said: “Parkinson’s is a fancy illness, and each affected person reacts to remedy otherwise. Our resolution equips clinicians with dependable, steady, and goal symptom insights which are simple to entry to successfully personalise remedies for every affected person. Our final objective is to enhance the high quality of life for each the sufferers and their households and tackle the cost-efficiency of the healthcare system.” 

Leave a Reply

Your email address will not be published. Required fields are marked *